Prism Medico & Pharmacy Ltd
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products[1]
- Market Cap ₹ 18.6 Cr.
- Current Price ₹ 30.7
- High / Low ₹ 31.0 / 12.5
- Stock P/E
- Book Value ₹ 21.7
- Dividend Yield 0.00 %
- ROCE 1.65 %
- ROE 1.09 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 35.1 to 21.0 days.
- Company's working capital requirements have reduced from 94.1 days to 14.5 days
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 25.0%
- Company has a low return on equity of -0.26% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | TTM | |
|---|---|---|---|---|
| 5.27 | 22.78 | 54.43 | 41.89 | |
| Interest | 0.14 | 0.29 | 0.11 | 0.18 |
| 5.21 | 21.95 | 54.10 | 42.07 | |
| Financing Profit | -0.08 | 0.54 | 0.22 | -0.36 |
| Financing Margin % | -1.52% | 2.37% | 0.40% | -0.86% |
| 0.07 | -0.03 | 0.07 | 0.08 | |
| Depreciation | 0.21 | 0.45 | 0.38 | 0.33 |
| Profit before tax | -0.22 | 0.06 | -0.09 | -0.61 |
| Tax % | 4.55% | 116.67% | -144.44% | |
| -0.22 | 0.00 | 0.04 | -0.55 | |
| EPS in Rs | -0.36 | 0.00 | 0.07 | -0.91 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -245% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 2% |
| 1 Year: | 92% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Sep 2019 | |
|---|---|---|---|---|
| Equity Capital | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | 6.81 | 6.81 | 6.85 | 7.10 |
| Borrowing | 3.50 | 2.18 | 2.27 | 0.00 |
| 0.89 | 0.75 | 6.03 | 11.73 | |
| Total Liabilities | 17.26 | 15.80 | 21.21 | 24.89 |
| 9.91 | 9.31 | 8.91 | 8.94 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 2.61 | 1.36 | 1.36 |
| 7.35 | 3.88 | 10.94 | 14.59 | |
| Total Assets | 17.26 | 15.80 | 21.21 | 24.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| 0.00 | 3.55 | -0.44 | |
| 0.00 | -2.53 | 0.00 | |
| 0.00 | -1.61 | -0.50 | |
| Net Cash Flow | 0.00 | -0.59 | -0.95 |
| Free Cash Flow | 0.00 | 3.63 | -0.44 |
| CFO/OP | 0% | 430% | -121% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| ROE % | -1.71% | -0.16% | 1.09% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings INR ・Standalone data |
|
|||||||||||
| Revenue from Agriculture Products INR Lacs ・Standalone data |
||||||||||||
| Key Management Personnel (KMPs) count ・Standalone data |
||||||||||||
| Trade Receivables Turnover ratio ・Standalone data |
||||||||||||
| Purchase of Stock-in-Trade (Medical Devices) INR ・Standalone data |
||||||||||||
| Revenue from Bathroom Fittings (Subsidiary) INR Lacs |
||||||||||||
| Revenue from Cattle Feed (Subsidiary) INR Lacs |
||||||||||||
| Sales to Related Party (Galaxy Pharma Kenya) INR Lacs ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Submitted Regulation 74(5) confirmation certificate for quarter ended 31 March 2026; no dematerialised shares reported.
-
Compliance-57 (5) : intimation after the end of quarter
7 Apr - Regulation 57(5) filing: no non-convertible securities or payment obligations due for Q1 2026.
-
Disclosures Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011 For The Financial Year Ended 31St March, 2026.
7 Apr - Promoters reported no share encumbrance during FY ended 31 March 2026.
-
Compliance-57 (5) : intimation after the end of quarter
6 Apr - No non-convertible securities; no interest, dividend or principal dues for Jan-March 2026.
-
Intimation Under Regulation 57(4) Of SEBI (LODR) Regulations, 2015.
30 Mar - Company states no interest/dividend/principal payable on non-convertible securities for April–June 2026 quarter.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
PMPL deals in chemicals, serums, chemical products, antibiotics, medicines, drugs,
pharmaceuticals, pesticides, dyes, soaps, oils, perfumes, cosmetics, patent medicines, etc.